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A B S T R A C T   
This report demonstrates the ability of a microfluidic device to maintain human Graves’ disease tissue enabling 
the isolation and characterisation of Graves’ disease specific exosomes. Graves’ disease (n = 7) and non-Graves’ 
disease (Hashimoto’s thyroiditis, n = 3; follicular adenoma, n = 1) human tissue was incubated in a microfluidic 
device for 6 days ± dexamethasone or methimazole and effluent was analysed for the size and concentration of 
extracellular vesicles (EV) using nanoparticle tracking analysis. Exosomes were isolated by centrifugation and 
characterised using Western blotting and qRT-PCR for miRNA-146a and miRNA-155, previously reported to be 
immunomodulatory. EV were detected in all effluent samples. No difference in concentration was observed in the 
EV released from Graves’ compared to non-Graves’ disease tissue and although the size of EV from Graves’ 
disease tissue was smaller compared to those from non-Graves’ disease tissue, the difference was not consistently 
significant. No effect of treatment was observed on the size or concentration of EV released. The exosome 
markers CD63 and CD81 were detectable in 2/5 Graves’ disease tissue exosomes and CD63 was also evident in 
exosomes from a single non-Graves’ sample. miRNA-146a and miRNA-155 were detectable in all samples with no 
difference between tissue cohorts. Treatment did not influence miRNA expression in exosomes isolated from 
Graves’ disease tissue. Although miRNA-146a and miRNA-155 were both elevated following treatment of non- 
Graves’ disease tissue with dexamethasone and methimazole, the increase was not significant. This study pro-
vides a proof of concept that incubation of tissue on a microfluidic device allows the detection, isolation and 
characterisation of extracellular vesicles from human tissue biopsies.   
1. Introduction 
Graves’ disease is an autoimmune disease affecting 3% of women 
and 0.5% of men (Antonelli et al., 2020). It is characterised by elevated 
circulating autoantibodies to the thyrotropin receptor (TRAB), these 
autoantibodies bind to the thyrotropin receptor (TSHR) on thyroid 
follicular epithelial cells stimulating thyroid growth and hormone syn-
thesis/secretion via cyclic adenosine monophosphate (cAMP) produc-
tion resulting in hyperthyroidism (Edo et al., 2019). Inflammation, 
characteristic of Graves’ disease can lead to thyroid associated orbito-
pathy/ophthalmopathy, an eye disease, which occurs in 30–50% of 
Graves’ disease patients, with 5% leading to blindness (Tanda et al., 
2013). Despite extensive research, the pathogenesis of this disease re-
mains unclear. 
Exosomes and microvesicles (collectively known as extracellular 
vesicles; EV) are membrane bound vesicles, released from all cells 
(Zhang et al., 2020; Fig. 1). They are found in all biological fluids, have a 
molecular profile representative of the cellular source and microvesicles 
are elevated in the blood of patients with Graves’ disease (Mobarrez 
et al., 2016). EV are thought to be key players in intercellular commu-
nication both locally and systemically and have been shown to activate 
the immune system and trigger inflammation in many disease states 
(Jiang et al., 2020; Yang and Liu, 2020; Lanyu and Feilong, 2019), either 
by direct stimulation of CD4+ T cells or via phagocytosis and presen-
tation by dendritic cells (Mittal et al., 2020). In addition, EV are able to 
inhibit the apoptosis of activated T cells exacerbating the inflammatory 
response, as shown in patients with rheumatoid arthritis whose EV, 
which have higher levels of membrane bound tumour necrosis factor-α 
compared with those from healthy controls, could prevent apoptosis in 
activated T cells (Zhang et al., 2006). 
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The main first line treatment for Graves’ disease involves the use of 
thionamides such as carbimazole or the metabolite methimazole, which 
reduce inflammation and thyroxine production (Kahaly, 2020). How-
ever, this class of drugs does not specifically target the underlying 
pathogenic process and when used for definitive management, relapse 
rates are high after withdrawal (40–60%; Liu et al., 2015). Other 
treatment options include radioiodine and/or surgical ablation both of 
which destroy/remove thyroid tissue resulting in high rates of hypo-
thyroidism (90–100%). Additional treatment with the 
anti-inflammatory corticosteroid, dexamethasone has been trialled 
(Mao et al., 2009), with the aim of down regulating the inflammatory 
response. The results of this trial showed a reduction in serum TRAB, 
thyroid volume and relapse rate following treatment (Mao et al., 2009). 
Patients with active, moderate/severe Graves’ ophthalmopathy are 
commonly treated with dexamethasone (Bartalena et al., 2016; 
Längericht et al., 2020), but the use of dexamethasone as a treatment for 
Graves’ disease per se remains controversial due to side effects including 
acute/severe liver damage (Mao et al., 2009). 
It is postulated that EV and specifically small EV/exosomes (sEV); 
containing specific microRNAs (miRNAs) released from Graves’ tissue 
may stimulate the inflammatory immune response, aggravating the 
disease further and contributing to Graves’ ophthalmopathy, as 
increased miRNA-155 (a single stranded, small, non-coding RNA) has 
the potential to promote ocular inflammation and proliferation in this 
disease (Ma et al., 2011; Li et al., 2014). MiRNA are small (17–25 nu-
cleotides) non-coding RNA, whose primary role is gene regulation 
(Catalanotto et al., 2016). If carbimazole and dexamethasone reduce the 
release of exosomes, therapies alternative to dexamethasone with its 
associated side effects, which target EV and/or their contents directly, 
can be developed. 
The majority of EV work to date has been carried out on either cell 
lines or serum/plasma. Although serum and plasma are a rich source of 
EV, they contain a mix of vesicles derived from various cell types of both 
healthy and diseased origin, making characterisation complicated. In 
contrast, those derived from cell lines are from a single cell source, 
which may not be representative of the multicellular nature of the tissue. 
The use of microfluidics to culture small (3mm3) pieces of human tissue 
(Bower et al., 2017; Cheah et al., 2017), provides the distinct advantage 
of being able to isolate EV known to originate from the diseased thyroid 
and associated cells. 
Although many researchers have reported the culture of a diverse 
range of human tissue explants/slices ex vivo under static conditions 
(Contartese et al., 2020), the clinical relevance of these models is un-
certain. Microfluidic systems have advanced ex vivo culture by providing 
a controlled fluid flow for nutrient exchange, removal of waste and also 
induce shear stress, aiming to recapitulate the in vivo microenvironment. 
Whilst many groups have successfully developed microfluidic devices to 
maintain engineered tissues/organoids, including brain, liver, heart, 
intestine, lung, skin and kidney (reviewed in Yu et al., 2019 and Duzagac 
et al., 2021), patient biopsies possess the whole gamut of cells and 
extracellular matrix present in the parent tissue which provides a closer 
representation of the disease. Recently, dynamic perfusion systems, 
including microfluidic based chips, have demonstrated the ability to 
maintain human organotypic cultures from tissues including heart, liver, 
ovary, breast, rectum and larynx (Hughes et al., 2021). The 3D 
complexity of the tissue is retained and mimics the in vivo environment, 
resulting in a significant advantage over in vitro 2D culture of artificially 
immortalised cell lines, which lack critical cellular interactions when 
studied in isolation. Ex vivo microfluidic models, span the gap between 
high throughput use of cell lines and complex, expensive in vivo models 
(McLean et al., 2018). 
The authors have developed and characterised several microfluidic 
devices for the successful maintenance of a variety of human tissues 
(cardiac tissue, and tumour biopsies from colorectal, thyroid and head 
and neck squamous cell carcinomas, HNSCC; Bower et al., 2017; Cheah 
et al., 2010, 2017; Hattersley et al., 2011; Carr et al., 2014; Dawson 
et al., 2016; Kennedy et al., 2019; Riley et al., 2019). The aim of the 
current study was to determine whether EV can be isolated and char-
acterised from effluent coming from the microfluidic devices containing 
Graves’ disease and non-Graves’ disease tissue. The effect of treatment 
with the clinically relevant drugs, dexamethasone and methimazole on 
EV release, size and miRNA content has also been investigated. 
Fig. 1. Schematic demonstrating exosome formation and release. Unlike microvesicles which are formed from the direct outward budding of the cell membrane, 
exosomes or sEV are formed from the inward budding of the endosomal membrane to form multivesicular bodies (MVB). The MVB either fuse with lysosomes and 
their content is enzymatically degraded, or they fuse with the cell membrane to release their contents as exosomes (adapted using (Zhang et al., 2020). 
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2. Materials and methods 
Ethical approval for the study was obtained from London Hamstead 
Research Ethics committee (17/LO/0209) and from Hull University 
Teaching Hospitals NHS Trust research and development (R2469). Tis-
sue samples were obtained from either patients with Graves’ disease (n 
= 7) or from patients with non-Graves’ related thyroid pathologies (n =
4; Hashimoto’s or follicular adenoma) undergoing total thyroidectomy 
following written informed consent (Table 1), from the ENT department 
at Castle Hill Hospital, Hull. 
2.1. Setting up and running microfluidic devices 
The microfluidic device was designed and manufactured in Hull out 
of Perspex (Fig. 2). The chip comprises a central, 4mm diameter 
chamber, to house the tissue, which is flanked by two Perspex screw in 
connectors, each containing 13 holes of 0.1mm diameter, connected via 
ethylene tetrafluoroethylene (ETFE) 1/16” tubing (Kinesis Ltd, St Neots, 
UK). The inlet tubing is connected to a 20ml syringe (Becton Dickinson, 
Wokingham, UK) via a 0.2μm filter (Sarstedt Ltd, Leicester, UK) and a 
one-piece leak free connector (Mengel Engineering, Denmark). 
On receipt of the tissue biopsy, the sample was divided using scalpels 
into pieces (~15mg each) before being placed into six separate micro-
fluidic devices, within 1hr of receipt, and perfused (2μl/min) using a 
calibrated pressure driven pump (PhD Harvard, 2000), with Dulbecco’s 
modified eagles medium (DMEM) containing 10% (v/v) exosome 
depleted foetal bovine serum (Gibco, Fisher Scientific), penicillin/ 
streptomycin (0.1U/ml and 0.1mg/ml respectively; Lonza, Castleford, 
UK) and L-glutamine (0.4mM; Lonza) alone or including final, physio-
logically relevant, concentrations of either methimazole (1μg/ml, 
Sigma) or dexamethasone (0.1μM, Sigma) in duplicate. The microfluidic 
devices were incubated at 37 ◦C and perfused continually for 6 days with 
daily effluent collection. Lactate dehydrogenase (LDH) was analysed 
using the cytotoxicity detection assay, following the manufacturers’ 
instructions (Merck, Feltham, UK), on effluent released from Graves’ (n 
= 4) and Non-Graves’ (n = 3) tissue throughout maintenance on the 
microfluidic device. Following the assay the absorbance was measured 
at 492 nm and normalised/mg of starting tissue. Lysis of the tissue was 
achieved with 10% lysis solution (provided in the kit). Remaining 
effluent was stored at − 80 ◦C prior to analysis and EV isolation, with 
each sample undergoing a single freeze thaw cycle. Hematoxylin and 
eosin staining of paraffin embedded tissue sections prior to and post 
microfluidic maintenance was performed as previously described (Riley 
et al., 2019). 
2.2. Nanoparticle tracking analysis (NTA) 
The effluents collected from all samples, following perfusion on the 
microfluidic device, were analysed for EV size and concentration using 
the Malvern Panalytical® NanoSight LM10. For each sample, three runs 
of 60 s were used to analyse the EV. The mean concentration of the 
particles was normalised/10mg of starting tissue for comparison be-
tween samples. 
2.3. Ultracentrifugation to isolate small extracellular vesicles (exosomes) 
EV were isolated from the tissue effluent coming from the micro-
fluidic device using sequential centrifugation steps as described by 
Théry et al. (2006). 
Briefly, the conditioned medium from duplicate devices were com-
bined from days 4, 5 and 6 of perfusion and centrifuged at 400 x g for 10 
min at 4 ◦C. The supernatant was transferred to a new falcon tube and 
sequentially centrifuged at 2, 000 x g (10 min), and 10, 000 x g at 4 ◦C 
(30 min; Beckman Coulter Ltd, High Wycombe, UK). Supernatants were 
transferred into OptiSeal tubes (Beckman Coulter) for ultracentrifuga-
tion in a TLA-110 fixed angle rotor at 100, 000 x g at 4 ◦C for 1 h 
(Beckman Optima MAX-XP). The sEV pellet was washed with PBS and 
ultracentrifuged again for 1h. The supernatant was removed and the 
tube inverted for 10 min prior to protein or RNA extraction. 
2.4. Western blot analysis of exosomal content 
Protein was extracted from sEV pellets (in the effluent from 5 Graves’ 
patient samples and one non-Graves’ tissue sample maintained on the 
microfluidic devices) using 20μl RIPA buffer containing PhosSTOP – 
phosphatase inhibitor cocktail and protease inhibitor cocktail complete 
ULTRA (Sigma). Lysates from replicate tubes were combined and incu-
bated for 15 min on ice before vortexing and sonication for 3 min to fully 
disrupt the sEV. Centrifugation at 4 ◦C for 15 min at 16,000 x g pelleted 
cell debris and the supernatant was analysed for protein content using 
the Pierce™ BCA protein assay kit (Thermofisher Scientific). 
Western blotting for the exosomal markers CD9, CD63 and CD81 was 
performed using the non-reducing Bolt system (Thermofisher Scientific) 
as described by Kowal et al. (2017). Briefly, 30μl of sEV extract was 
added to 10μl of 4 × Bolt sample buffer (Thermofisher Scientific) and 
heated to 70 ◦C for 10 min before loading onto a 4–12% Bis-Tris gel 
(Thermofisher Scientific) submerged in 1 × MES running buffer. Pro-
teins were separated at 150V until the dye front reached the bottom of 
the gel before being transferred onto PVDF membranes (BioRad) using 
the BioRad Turbo Transblot semi-dry transfer system. 
PVDF membranes were blocked in 5% (w/v) milk powder in TBS- 
Tween-20 (0.1% v/v) for 1hr before being probed with primary anti-
bodies for CD9 (C-4; 1:250–1:2000), CD63 (MX-49.129.5; 
1:500–1:2000), CD81 (0.N.165; 1:250–1:500; Santa Cruz/Insight 
Table 1 
Patient clinicopathological characteristics.  
Sample No Graves’ or non Graves’ Sex Age NTA WB qRTPCR 
GRA11 Graves’ F 61 ✓ – ✓ 
GRA12 Graves’ F 44 ✓ ✓ ✓ 
GRA13 Graves’ M 47 ✓ ✓ ✓ 
GRA14 Graves’ F 62 ✓ ✓ ✓ 
GRA15 Graves’ F 53 ✓ ✓ ✓ 
GRA16 Follicular adenoma F 39 ✓ – ✓ 
GRA17 Graves’ F 23 ✓ – ✓ 
GRA18 Hashimoto’s F 66 ✓ ✓ – 
GRA19 Graves’ F 36 ✓ ✓ – 
GRA20 Hashimoto’s F 29 ✓ – ✓ 
GRA21 Hashimoto’s F 75 ✓ – ✓ 
NTA, nanoparticle tracking analysis; WB, Western blotting; qRTPCR, quantita-
tive reverse transcriptase polymerase chain reaction. 
Fig. 2. Schematic of a continuous flow microfluidic device. A rectangular de-
vice (15 x 10 × 10 mm) has been CNC milled out of PMMA (Perspex). The inner 
core is a cylinder 4mm in diameter which houses the tissue. On each side, 
tubing (ethylene-tetrafluoroethylene, 0.8mm internal diameter) is connected 
via a port with 13 holes of 0.1 mm diameter to create an even flow (2μl/min) of 
fluid across the tissue. The chamber is sealed with two O-rings (4 mm inner 
diameter, 1 mm thickness). 
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Biotechnology, Middlesex, UK) for either 1hr at room temperature or 
overnight at 4 ◦C. Following 3 × 10min washes with TBS-Tween (0.1%), 
primary antibodies were detected using mouse-IgG Kappa binding 
protein-HRP (1:5000; Insight Biotechnology) for 1hr before further 
washes and chemiluminescent detection (SuperSignal™ West Pico PLUS 
Chemiluminescent Substrate; Thermofisher Scientific) and X-ray 
autoradiography. 
2.5. RNA extraction and qRT-PCR 
RNA was extracted from each sEV pellet following ultracentrifuga-
tion (sEV collected from 6 Graves’ tissues and 3 non-Graves’ tissues) 
using the miRNeasy micro kit (Qiagen, Manchester, UK), following the 
manufacturer’s instructions. Briefly, 700μl of Qiazol reagent (Qiagen, 
Manchester, UK) was added to each sEV pellet followed by 140μl chlo-
roform. Following incubation for 2–3min the suspension was centri-
fuged at 12, 000 x g at 4 ◦C for 15 min to separate the phases. The upper 
aqueous phase was combined with 1.5 vol of 100% ethanol and applied 
to an RNeasy MiniElute spin column in a 2ml collection tube, before 
centrifuging at >8000 x g for 15s at room temperature. The column was 
washed with RWT (700μl) and RPE buffers (500μl; supplied) followed by 
80% ethanol (500μl) with centrifugation at >8000 between each. The 
spin column was dried by centrifuging at 16, 000 x g for 5 min, before 
being placed in a new collection tube. RNase free water (14μl) was 
applied to the column before centrifugation at 16, 000 x g for 1 min to 
elute the RNA. This was stored at − 80 ◦C prior to cDNA synthesis. 
cDNA was synthesised using the miRCURY locked nucleic acid (LNA) 
RT kit (Qiagen), following the manufacturer’s instructions using 4μl of 
prepared RNA. The reaction mix was incubated for 60 min at 42 ◦C with 
a 5 min denaturation step at 95 ◦C. 
qRT-PCR was performed using the miRCURY SYBR green PCR kit 
(Qiagen) with individual miRCURY LNA miRNA PCR assays using 
manufactured primers for hs-miRNA-146a-5p and hs-miRNA-155–5p 
(Qiagen). Primers for hs-miRNA-16–5p (Qiagen) were used as an 
endogenous control (Lee et al., 2015), following trials using the same 
amount of RNA from both treated and untreated samples and being 
shown not to alter with treatment. Each PCR reaction mixture was 
prepared using 2 × miRCURY SYBR green Master mix (5μl), ROX 
reference dye (0.5μl), LNA primer mix (1μl) and RNAse free water 
(0.5μl). cDNA (3μl, 1:30 diluted) was added to triplicate wells of an 
Applied Biosystems™ MicroAmp™ Fast Optical 96-well reaction plate, 
along with 7μl of reaction mix. Following a brief centrifuge the PCR was 
completed on an ABI StepOnePlus™ system with the following settings: 
Initial heat activation 95 ◦C for 2 min followed by 40 cycles of 95 ◦C for 
10 s and 56 ◦C for 60 s. Melt curve analysis was performed at 60–95 ◦C. 
Relative expression/fold change of miRNA-146a and miRNA-155 rela-
tive to miRNA-16 was determined using the comparative cycle threshold 
(CT) method (2-ΔΔCT; Livak and Schmittgen, 2001). 
2.6. Statistical analysis 
Two-way ANOVA (GraphPad Prism v.9.1.0; 221) with bonferroni 
correction was used to determine changes in the release of extracellular 
vesicles over time and with treatment and to compare between Graves’ 
and non-Graves’ samples. One-way ANOVA was used with multiple 
comparisons to compare miRNA expression in exosomes extracted 
following both treatments to the control using Dunnetts’ test. The 
expression of each miRNA in the sEV was compared between those 
extracted from Graves’ tissue and those extracted from non-Graves’ 
tissue for both dexamethasone treated and methimazole treated samples 
using Mann Whitney U test. 
3. Results 
3.1. Lactate dehydrogenase release from thyroid tissue maintained on the 
microfluidic device 
A higher level of LDH release was observed at the start of the 
experiment reflecting the tissue damage during slicing. This decreased 
to a basal level throughout the remainder of the experiment (represen-
tative result shown in Fig. 3). Lysis of the tissue at the end showed an 
increase in LDH indicating the presence of viable cells. 
3.2. The release of extracellular vesicles from graves’ and non-graves’ 
tissue maintained on the microfluidic device 
NTA was carried out on the effluent collected from all the thyroid 
tissue samples with and without dexamethasone and methimazole. An 
initial high level of EV release was observed between 0 and 3 days in 
both types of tissue (Fig. 4) which significantly decreased over time 
(p<0.0001) before stabilizing throughout days 4–6 (~2.95 x 108 parti-
cles/ml/10mg tissue). No significant difference in the concentration of 
particles released was observed between Graves’ and non-Graves’ tissue. 
The mean size of particles released, ranged from 138nm to 233nm, with 
a significant decrease in size observed in both tissue types over time 
(Fig. 5; p<0.0001). At each time point the size of particles released from 
non-Graves’ tissue was greater than those released from Graves’ tissue 
however, the difference was only significant at the 0–4hr time point (p 
= 0.0007; control, p = 0.0102; dexamethasone and p<0.0001; 
methimazole). 
3.3. The effect of treatment on the release of extracellular vesicles from 
graves’ and non-graves’ tissue 
The results from individual patients were variable and although both 
dexamethasone and methimazole appeared to increase particle release 
over the first three days in non-Graves’ tissue, no consistent or signifi-
cant treatment effects were observed in either tissue cohorts (Fig. 4). 
Treatment also had no significant effect on the size of the particles 
released from tissue. 
Fig. 3. Lactate dehydrogenase (LDH) release from a representative non-Graves’ 
disease tissue throughout maintenance on-chip. Control, medium only (chip A 
and B), dexamethasone treated (chip C and D), methimazole treated (chip E and 
F). LDH release following lysis of tissues from chip A, D, E and H indicated by 
the arrow. The mean absorbance/mg tissue ± SD from duplicate readings of the 
effluent is displayed. Insert shows hematoxylin and eosin stained non-Graves’ 
tissue pre and post on-chip maintenance ×400 magnification. 
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3.4. Detection of CD9, CD63 and CD81 on EV released from graves’ and 
non-graves’ disease tissue 
Following combination of the effluents from days 4, 5 and 6, the 
approximate volume processed from each sample for sEV isolation was 
4.5ml. The protein concentration obtained from the subsequent sEV 
lysates ranged from 48.5 to 231μg/ml, however the maximum volume of 
30μl of protein lysate was added to appropriate wells to give the best 
chance of detection. CD63 was detected in the sEV released from 2/5 
Graves’ disease tissues and from the single non-Graves’ tissue investi-
gated (Fig. 6A), whereas CD81 was only detected in the sEV released 
from 2 of the Graves’ patients (Fig. 6B). CD9 was not detectable in any of 
the sEV lysates. 
3.5. miRNA expression in EV released from Graves’ and non-Graves’ 
tissue 
The volume of effluent used for sEV isolation and RNA extraction is 
shown in Table 2. Detectable amounts of RNA, measured using nano-
drop, were found in all samples and this ranged from 7.9ng/μl up to 
43,7ng/μl. Surprisingly, the amount of RNA extracted was not always 
proportional to the volume of starting effluent shown by the ratio of 
RNA concentration/starting volume (Table 2). In the Graves’ patients (n 
= 6), both miRNA-146a and miRNA-155 were detectable in all cases, but 
there was no significant effect of treatment on the expression as deter-
mined using fold change compared to control (2-ΔΔCT) with one-way 
ANOVA (Dunnetts’ test; Fig. 7A). In contrast, both miRNA-146a and 
miRNA-155 appeared to increase in expression in the exosomes released 
from non-Graves’ tissue, following treatment with both dexamethasone 
and methimazole, with methimazole having a greater effect (Fig. 7B). 
However, only three non-Graves’ samples were used for qRT-PCR and 
the variation within these patients was substantial, meaning that the 
differences were not significant. In addition, no significant difference in 
the expression of either miRNA-146a or miRNA-155 was observed be-
tween Graves’ disease exosomes and non-Graves’ disease exosomes 
when comparing the fold change for both treatments. 
4. Discussion 
This report has demonstrated, for the first time, the isolation of 
tissue-specific sEV from small pieces of human tissue maintained on a 
microfluidic device. It has shown that these vesicles can be quantified 
using NTA and the sEV can be retrieved and characterised using mo-
lecular techniques. Although the effluent was frozen prior to analysis, 
which can reduce the numbers of detectable EV, there were still a sub-
stantial amount of EV present, observed using NTA, even after a 1:4 
dilution, therefore any clear treatment effects should still be observed. 
Isolation of EV from tissue has, until now, been limited to the 
extraction from the interstitial space of, for example; mouse brain and 
lung tumours, using gentle tissue dissociation followed by ultracentri-
fugation and sucrose density gradient centrifugation (Hurwitz et al., 
2019; Perez-Gonzalez et al., 2017). 
The use of dynamic microfluidic tissue perfusion to maintain func-
tional (thyroxine production throughout culture) benign and thyroid 
tumour tissue, for up to 4 days, has been demonstrated previously by the 
authors (Riley et al., 2019). Riley and colleagues demonstrated that 
thyroid tissue viability was unaffected by microfluidic culture using 
propidium iodide and trypan blue staining of dissociated cells. In 
agreement with the current study, tissue morphology (H&E) was not 
affected by maintenance on-chip and LDH release was initially elevated, 
likely due to tissue manipulation and subsequently decreased to minimal 
levels over the period of maintenance on-chip. An increase in the LDH 
release following cell lysis, as demonstrated in both studies, indicates 
Fig. 4. Nanoparticle tracking analysis of extracellular vesicles (concentration) 
released from A) Graves’ biopsy samples (n = 7) and B) non-Graves’ biopsy 
samples (n = 4), maintained on the microfluidic device over a 6 day period 
(diluted 1:4 with serum free medium), to investigate the effect of treatment on 
extracellular vesicle release. The mean concentration of EV released from the 7 
Graves’ samples and the 4 non-Graves’ samples are expressed as particles/ml/ 
10mg starting weight of tissue ± SD. A significant decrease in particle release 
was observed over time from both tissue types (p<0.0001), Two Way ANOVA. 
Fig. 5. Nanoparticle tracking analysis of extracellular vesicles (size) released 
from A) Graves’ biopsy samples (n = 7) and B) non-Graves’ biopsy samples (n 
= 4), maintained on the microfluidic device over a 6 day period (diluted 1:4 
with serum free medium). The mean size (nm) from the 7 Graves’ samples and 
the 4 non-Graves’ samples ± SD is displayed. A significant decrease in particle 
size was observed over time from both tissue types (p<0.0001), Two 
Way ANOVA. 
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Fig. 6. Western blot analysis of EV released from a representative Graves’ disease tissue sample, incubated on a microfluidic device. A) CD63 B) CD81. EV released 
from; lane 1, control tissue; lane 2, dexamethasone treated tissue; lane 3, methimazole treated tissue. MM – Magic Mark XP western protein standard. 
Table 2 
RNA concentration of the lysate obtained from EV released from Graves’ and non-Graves’ tissue maintained on a microfluidic device.  
Graves’ Treatment Volume extracted from (ml) RNA concentration (ng/μl) Ratio of RNA concentration/original volume 
GRA11 Control 4.7 ND –  
Dexamethasone 4.7 16.1 3.4  
Methimazole 4.7 8.6 1.8 
GRA12 Control 4.7 7.5 1.6  
Dexamethasone 4.7 8.8 1.9  
Methimazole 4.7 8.2 1.7 
GRA13 Control 4.7 8.6 1.8  
Dexamethasone 3.7 15.4 4.2  
Methimazole 4.7 12 2.6 
GRA14 Control 6 25.2 4.2  
Dexamethasone 6 13.7 2.3  
Methimazole 3.7 10.1 2.7 
GRA15 Control 3.0 14 4.7  
Dexamethasone 3.0 13.9 4.6  
Methimazole 4.6 15.3 3.3 
GRA17 Control 13.4 39.9 3.0  
Dexamethasone 14.1 35.4 2.5  
Methimazole 9.4 10.9 1.2 
Non-Graves’     
GRA16 Control 9.4 43.7 4.7  
Dexamethasone 9.4 39.3 4.2  
Methimazole 9.4 33.3 3.5 
GRA20 Control 2.6 9.9 3.8  
Dexamethasone 4.1 7.9 1.9  
Methimazole 4.7 41.2 8.8 
GRA21 Control 4.5 10.5 2.4  
Dexamethasone 4.6 25.7 5.6  
Methimazole 4.5 15.9 3.5 
ND = Not done. 
Note: Volume varied due to the use of effluent for nanosight analysis and western blotting in addition to RNA extraction. 
Fig. 7. qRT-PCR analysis of miRNA-146a and miRNA-155 in EV released from A) Graves’ tissue (n = 6) and B) non-Graves’ tissue (n = 3) maintained on a 
microfluidic device. Expression was normalised against miRNA-16 and fold change was calculated using 2− ΔΔCT. The mean fold change from the 6 Graves’ and 3 non- 
Graves’ tissues ± SD is displayed. 
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the presence of viable cells at the end of the culture period. In addition 
Riley et al. (2019), used bromodeoxyuridine (BrdU) perfusion for the 
final 24 h  of on-chip maintenance to demonstrate not only full thickness 
penetration of soluble medium constituents, but also on-chip prolifera-
tion evidenced by BrdU detection using immunohistochemistry. Further 
support for the retention of cell viability was demonstrated by Riley 
et al., through the detection of no change in apoptotic cells prior to and 
post microfluidic maintenance (Riley et al., 2019), as well as an array of 
secreted cytokines released from the same thyroid tumour tissue (Riley 
et al., 2021). To date the maintenance of ex vivo human tissue in dy-
namic perfusion systems has focussed mainly on the tissue itself and how 
time on-chip, or treatment affects the tumour architecture, protein 
expression and markers of viability and apoptosis, with a few looking at 
leakage of markers of cell death into the effluent (Hughes et al., 2021). 
This report however, is the first to report the use of microfluidic tech-
nology to isolate EV released from tissue maintained in a pseudo in vivo 
state. The use of microfluidic technology to isolate and characterise 
thyroid exosomes specific to disease pathology, utilising tissue biopsies, 
provides future potential to diagnose and monitor disease in a minimally 
invasive way using serum, urine or even tear fluid. Han et al., has 
observed that tear fluid exosomes are elevated in patients with thyroid 
eye disease compared to healthy controls and that these exosomes can 
induce inflammatory cytokine release from orbital fibroblasts in vitro 
(Han et al., 2021). 
In the current study, EV were detectable in the microfluidic effluent 
throughout the six days of the experiment, following a similar pattern to 
the LDH release observed previously (Riley et al., 2019), with higher 
levels at the beginning of the experiment, again likely due to cellular 
disruption during experimental set-up, significantly decreasing to lower 
levels by day 4. It is probable that the EV in the initial effluent will 
consist of debris and apoptotic bodies, which is why the effluent from 
day 4 onwards was focussed on for the subsequent experiments. In 
contrast to Mobarrez et al. (2016), who found an elevated level of 
microvesicles in the plasma of Graves’ disease patients compared to 
controls, using flow cytometry, and a reduction following treatment 
with thiamazole, no difference was observed in the levels of EV released 
from Graves’ vs. non-Graves’ disease tissue or with methimazole or 
dexamethasone treatment using NTA in the current study. However, the 
treatment time in the patients was months, compared to days in this ex 
vivo study and the in vivo drug treatment may affect EV release from 
other tissues. In the current study, the direct effect of dexamethasone 
and methimazole on exosome release were investigated, however, it 
should be noted that the effect of these drugs may be to influence the 
downstream effect of EV, which needs to be investigated further. 
The nomenclature of extracellular vesicles according to the Inter-
national Society for Extracellular Vesicles (ISEV), refer to vesicles with a 
size <200 nm as small extracellular vesicles (sEV) and those >200 nm as 
medium/large EV (m/lEV; Théry et al., 2018). In this context, the ves-
icles detected in the current study, following the initial settling down 
period, would be classed as sEV with only a few larger particles being 
released over the first few hours. Treatment did not result in a difference 
in the size of the vesicles released, suggesting apoptosis was not initiated 
during the 6 day period and although the size of the particles was 
consistently higher from the non-Graves tissue compared to those from 
Graves’ tissue, this difference was not significant. 
The classic exosomal markers, CD63 and CD81, were detected in a 
proportion of the samples investigated. However, a greater volume of 
tissue effluent is required to enable enhanced isolation and identifica-
tion of proteins of interest in the tissue specific exosomes released during 
microfluidic maintenance. Exosomes from the serum of Graves’ disease 
patients, carrying the TSH-R, IGF-1 and HSP-60 have been shown pre-
viously to induce an inflammatory response in vitro through the Toll-like 
receptor/NFκB signaling pathway, which may contribute to the patho-
genesis of Graves’ disease (Cui et al., 2021). The expression of IGF-1R on 
the exosomes released from Graves’ disease tissue provides a potential 
mechanism for the success of treatment of Graves’ disease patients with 
ophthalmopathy with Teprotumumab, an immunotherapy targeting this 
receptor (Douglas et al., 2020; Smith, 2020). These studies, emphasize 
the importance of further protein characterisation of disease specific 
exosomes from biopsy tissue. 
The dysregulated expression of miRNA has been identified as playing 
a crucial role in the pathogenesis of several autoimmune diseases (Long 
et al., 2018), including Graves’ disease (Martinez-Hernandez et al., 
2019). A number of miRNAs have been found to be differentially 
expressed in the serum of patients with Graves’ disease compared to 
those with either disease in remission (Hiratsuka et al., 2016) or healthy 
controls (Yao et al., 2019; Qin et al., 2015). 
The current study investigated the presence of two known regulators 
of the inflammatory response, in exosomes released from both Graves’ 
and non-Graves’ tissue; miRNA-155 and miRNA-146a (Marques-Rocha 
et al., 2015). Although miRNA-146a and miRNA-155 were detectable in 
all tissue exosome samples, no difference in the levels expressed be-
tween the two cohorts was observed. This is in contrast to a study by 
Wang et al. (2017), who found a significantly elevated expression of 
miRNA-146a in the plasma of patients with Graves’ disease (n = 27) 
compared to controls (n = 15). They also found that miRNA-146a 
directly targets Notch 2 signaling, increasing the expression of proin-
flammatory IL6. However, interestingly both miRNA-146a and 
miRNA-155 were demonstrated to be lower in the serum of Graves’ 
disease patients (n = 80) compared to healthy controls (n = 65) by 
Zheng et al. (2018). Importantly, miRNA-146a and miRNA-155 are 
elevated in thyroid eye disease orbital fibroblasts, whereas the expres-
sion of their targets PTEN and ZNRF3, which both inhibit proliferation, 
were decreased following TSH treatment of orbital fibroblasts (Woeller 
et al., 2019), however, as stated previously these studies are looking at 
whole body EV in contrast to the tissue specific EV the current study was 
investigating. 
5. Conclusion 
This proof of concept study provides a unique way to isolate tissue 
specific sEV/exosomes, providing the potential for rigorous screening of 
these EV to identify biomarkers of disease and disease severity to enable 
earlier identification of disease, progression monitoring throughout 
treatment and evidence based, personalised treatment regimens. 
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